Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesIovance Biotherapeutics Inc

Iovance Biotherapeutics Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
8.565 USD 0.53 ( 6.53%)
Last update at 2026-11-09T15:21:00Z
VOLUME
2321108
Market Cap
4239.81M

Momentum Score

…

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
7.81
Low
8.56
High
52 Week Price Range
1.76
Low
9.41
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Iovance Biotherapeutics is a clinical-stage biotechnology company developing tumor-infiltrating lymphocyte (TIL) therapies for solid tumors, with lead program lifileucel targeting advanced melanoma and programs in other solid cancers. Long-term growth drivers include positive clinical data toward regulatory approvals, scalable manufacturing and commercialization partnerships, and broader adoption of cell therapies for solid tumors. The company appears positioned to benefit from successful trial outcomes and execution on manufacturing scale-up.
Investors should monitor risks from clinical and regulatory setbacks, complex and costly manufacturing scale-up, significant funding needs, and competitive and reimbursement pressures.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
8.04
Dividend Yield
-
Revenue TTM
324.97M
Revenue Per Share
0.79
Gross Profit TTM
157.29M
Debt / Equity
0.07
ROE
-40.36%
Net Debt
-114.63M
ROCE
-50.73%
Diluted EPS TTM
-0.69

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -393.05M -375.00M -447.52M -395.89M -342.25M
Net income -390.98M -372.18M -444.04M -389.92M -327.82M
Selling general administrative 152.32M 51.80M 27.70M 104.10M 83.66M
Selling and marketing expenses - 101.22M 79.22M - -
Gross profit 256.22M 40.08M -9.57M - -
Reconciled depreciation 47.32M 43.61M 29.12M 21.14M 13.98M
Ebit -393.05M -375.00M -447.52M -420.01M -356.68M
Ebitda -357.11M -331.40M -414.39M -398.88M -342.70M
Depreciation and amortization 35.94M 43.61M 33.13M 21.14M 13.98M
Non operating income net other - - - - 0.45M
Operating income -403.36M -395.28M -460.56M -398.88M -342.70M
Other operating expenses 666.86M 559.35M 461.75M 398.88M 342.70M
Interest expense - - - 2.98M 0.45M
Tax provision -2.07M -2.83M -3.48M - -
Interest income 10.31M 20.27M 11.64M 2.98M 0.45M
Net interest income 10.31M 20.27M 11.64M 2.98M 0.45M
Income tax expense -2.07M -2.83M -3.48M -5.97M -14.43M
Total revenue 263.50M 164.07M 1.19M 0.00M 0.00M
Total operating expenses 659.57M 435.35M 450.99M 398.88M 342.70M
Cost of revenue 7.29M 124.00M 10.76M - -
Total other income expense net 10.31M 20.27M 13.04M 2.98M 0.45M
Net income from continuing ops -390.98M -372.18M -432.98M -395.89M -342.25M
Net income applicable to common shares - - - -395.89M -342.25M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 913.17M 910.43M 780.35M 663.98M 777.33M
Intangible assets 279.32M 282.40M 229.26M - -
Other current assets 11.58M 12.38M 17.46M 7.27M 3.55M
Total liab 214.59M 200.02M 195.74M 164.34M 155.67M
Total stockholder equity 698.58M 710.40M 584.61M 499.64M 621.66M
Other current liab 112.16M 81.94M 69.41M 52.30M 56.77M
Common stock 0.02M 0.01M 0.01M 0.01M 0.01M
Capital stock 0.02M 0.02M 0.01M 0.01M 0.01M
Retained earnings -2775.53M -2384.55M -2012.38M -1568.34M -1172.44M
Other assets - - - 185.71M 777.33M
Cash 163.08M 115.69M 114.89M 231.73M 78.23M
Total current liabilities 138.36M 122.34M 110.31M 91.48M 89.20M
Current deferred revenue - - 0.00M - -
Net debt -114.63M -57.43M -39.03M -147.28M -6.70M
Short term debt 4.04M 12.90M 7.78M 12.59M 5.06M
Short long term debt 1.00M - - - -
Short long term debt total 48.44M 58.26M 75.86M 84.45M 71.53M
Other stockholder equity 3457.65M 3095.99M 2594.45M 2068.87M 1794.69M
Property plant equipment - - - 178.25M 100.94M
Total current assets 442.69M 457.02M 307.85M 471.85M 507.96M
Long term investments - - - 0.00M 91.59M
Net tangible assets - - - 499.63M 621.66M
Short term investments 133.90M 208.09M 164.98M 240.11M 426.18M
Net receivables 82.45M 69.34M 0.15M - -
Long term debt - 1.00M 1.00M 1.00M 1.00M
Inventory 51.68M 51.52M 10.37M - -
Accounts payable 22.16M 27.51M 33.12M 26.60M 27.38M
Accumulated other comprehensive income 16.44M -1.05M 2.53M -0.90M -0.60M
Preferred stock total equity - - - - 0.00M
Retained earnings total equity - - - - -1172.44M
Non currrent assets other 14.15M 6.73M 0.27M -171.82M 7.87M
Non current assets total 470.48M 453.41M 472.50M 6.43M 269.38M
Capital lease obligations 48.44M 57.26M 74.86M 84.45M 70.53M
Long term debt total - - - - 1.00M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 81.33M -96.41M -81.94M 256.45M 37.71M
Change to liabilities - - - 5.88M 27.66M
Total cashflows from investing activities 47.50M -96.41M -155.24M 256.45M 0.13M
Net borrowings - - 0.00M - 1.00M
Total cash from financing activities 300.77M 390.66M 462.96M 190.15M 239.27M
Change to operating activities - - - -8.78M 17.58M
Net income -390.98M -372.18M -444.04M -395.89M -342.25M
Change in cash 47.38M -59.27M -56.84M 153.85M 11.46M
Begin period cash flow 122.05M 181.32M 238.16M 84.31M 72.85M
End period cash flow 169.06M 122.05M 181.32M 238.16M 84.31M
Total cash from operating activities -302.41M -352.98M -361.82M -292.76M -227.94M
Issuance of capital stock 306.31M 397.30M 652.78M 189.50M 203.16M
Depreciation 34.46M 43.61M 33.13M 21.14M 13.98M
Change to inventory -14.21M -39.92M -10.12M - -
Change to account receivables -13.11M -69.19M -0.15M - -
Sale purchase of stock 1.51M - 2.41M 1.66M 1.59M
Other cashflows from financing activities -7.06M -6.64M -0.32M -1.01M 34.53M
Change to netincome - - - 84.89M 69.77M
Capital expenditures 33.84M 11.07M 22.29M 20.43M 37.57M
Cash flows other operating - - - - 7.76M
Cash and cash equivalents changes - - - - 11.46M
Change in working capital -24.27M -122.56M -6.52M -2.89M 24.55M
Stock based compensation 61.58M 109.63M 62.62M 84.02M 69.77M
Other non cash items 18.87M -8.65M -3.54M 0.87M 6.01M
Free cash flow -336.24M -364.05M -384.11M -313.18M -265.51M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
IOVA
Iovance Biotherapeutics Inc		 0.53
6.53%		 8.56 - - 13.05 5.87 12.84 -8.68
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Iovance Biotherapeutics Inc

Iovance Biotherapeutics, Inc., a commercial-stage biopharmaceutical company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States and internationally. The company offers Amtagvi, an individualized T cell therapy for solid tumor cancer and for the treatment of adult patients with previously treated advanced, or unresectable or metastatic melanomal; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic melanoma and metastatic renal cell carcinoma. It also develops lifileucel for the treatment of melanoma, cervical cancer, non-small cell lung cancer (NSCLC), endometrial cancer, and head and neck squamous cell carcinoma (HNSCC); LN-145-S1 to treat melanoma and HNSCC; LN-145 Gen 3 and core biopsy for the treatment of NSCLC; LN-145 Gen 3 to treat melanoma and HNSCC; IOV-2001 to treat chronic lymphocytic leukemia and small lymphocytic lymphoma; IOV-4001 for the treatment of melanoma and NSCLC; and IOV-3001 for use in the TIL therapy treatment regimen. The company has collaborations and licensing agreements with National Institutes of Health; the National Cancer Institute; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

825 Industrial Road, San Carlos, CA, United States, 94070

650 260 7120

https://www.iovance.com

975

Name Title Year Born
Dr. Frederick G. Vogt Esq., J.D., Ph.D. Interim CEO, Pres, Gen. Counsel & Corp. Sec. 1974
Mr. Jean-Marc Bellemin M.B.A. Chief Financial Officer & Principal Accounting Officer 1972
Dr. Igor P. Bilinsky Chief Operating Officer 1973
Dr. Friedrich Graf Finckenstein M.D. Chief Medical Officer 1967
Ms. Sara Pellegrino VP of Investor Relations & PR NA
Ms. Tracy Winton Sr. VP of HR NA
Mr. Howard B. Johnson M.B.A. Chief Bus. Officer 1960
Mr. James Ziegler M.B.A. Exec. VP of Commercial NA
Mr. Madan Jagasia Exec. VP of Medical Affairs NA
Dr. Raj K. Puri M.D., Ph.D. Exec. VP of Regulatory Strategy & Translational Medicine NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.93
+37.83%
MOON
CAD 4.86
+10.20%
HG
CAD 4.43
+9.93%
EPRX
CAD 10.57
+8.86%
NUAG
CAD 8.66
+8.79%
CSU
CAD 3257.60
-7.63%
DIV
CAD 3.85
-5.53%
TOI
CAD 99.00
-5.52%
BSX
CAD 0.82
-4.65%
LMN
CAD 26.79
-4.63%

Equity Sectors*

  • Basic Materials

    +3.88%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.16%

  • Financial Services

    +1.33%

  • Healthcare

    +1.50%

  • Industrials

    +2.97%

  • Real Estate

    +0.41%

  • Technology

    +1.27%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…